During a Case-Based Roundtable® event, Mark Pegram, MD, discussed the TROPiCS-02 trial of sacituzumab govitecan in hormone receptor–positive breast cancer in the first article of a 2-part series.
Targeted Oncology: Could you describe the TROPiCS-02 trial (NCT03901339) that led to the approval of sacituzumab govitecan (Trodelvy) in patients with hormone receptor–positive, HER2-negative breast cancer?
MARK PEGRAM, MD: [Concerning] the TROPicS-02 clinical trial design, it was a phase 3 study in patients with metastatic hormone receptor–positive disease who had received at least 1 endocrine therapy, a taxane and CDK4/6 inhibition in any setting. If you had somebody on adjuvant CDK4/6 inhibitor in the modern era, or they received neoadjuvant or adjuvant taxane, that all counted for eligibility in this trial. [Patients on the trial] had received least 2 but not more than 4 lines of chemotherapy for metastatic disease in the patient population in this trial, and must have had measurable disease by RECIST. They [received] treatment with sacituzumab govitecan at 10 mg/kg IV on day 1 and 8 on a 21-day cycle, or treatment of physician’s choice with capecitabine, vinorelbine, gemcitabine, or eribulin. The primary end point was progression-free survival [PFS] by a blinded independent committee review.1
What are the key efficacy outcomes observed in this trial?
[Looking at] topline data for the primary end point of PFS: there was a statistically significant improvement in PFS favoring patients who were randomly assigned to sacituzumab govitecan as compared with chemotherapy.2 The HR is 0.65 [95% CI, 0.53-0.81; nominal P = .0001], so [these are] impressive results for this agent. Overall survival [OS] also favored [sacituzumab govitecan with] an HR of 0.79 [95% CI, 0.65-0.95, P = .0133]. So, there was a survival benefit over chemotherapy for an antibody-drug conjugate [ADC] targeting TROP2 with a topoisomerase-I inhibitor payload.
These [PFS and OS] data were updated at the 2023 American Society of Clinical Oncology Annual Meeting.2 The responses were more modest, 21% [with sacituzumab govitecan vs 14% with chemotherapy]. But in the clinic, we all make treatment decisions on clinical benefit rate, that is responders plus stable disease, hopefully long term. The clinical benefit rate in this paper was [defined as] responders plus disease stability for at least 6 months or more. That is a more respectable fraction, over a third of the patients had that and that was statistically significantly better than chemotherapy control in this trial [34% vs 22%, odds ratio 1.80; 95% CI, 1.23-2.63; P = .0025]. Duration of response was approximately 8 months compared with less than 6 months for chemotherapy.2
What should physicians know about the tolerability and management of sacituzumab govitecan in this patient population?
You have to be mindful of adverse events [AEs] with sacituzumab govitecan because it does have some chemotherapy-like AEs.2 It does cause cytopenias, not dissimilar from chemotherapy. It also is moderately emetogenic, so you need to use antiemetics routinely as a premedication for this agent. It can cause diarrhea, which is also in the prescribing information, so be mindful of that and dose modify or [use] comedication accordingly. There can also be alopecia, [which occurred] in half the patients, some fatigue [was seen] in almost one-third, anorexia [in 21%], and aspartate aminotransferase elevation in [approximately] 10%. It's not like trastuzumab emtansine [T-DM1; Kadcyla], and it doesn’t cause thrombocytopenia like T-DM1 does either, or as much transaminase elevation, but T-DM1 is a pretty easy ADC to use. It was the first one that we all got used to using back in the day. [Sacituzumab govitecan] was a little bit more challenging in terms of safety signals, but if you control these, it can be extremely well tolerated.
Focusing on the AEs of grade 3 or higher, we see about half the patients have neutropenia. Hardly anybody had grade 3 thrombocytopenia, only 1 patient out of 268, so that's distinctly unusual. There was some [grade 3 or 4] diarrhea in approximately 10% [of patients]. There was a bit of upper gastrointestinal toxicity, but only [grade 3 or higher in] 1%. Abdominal pain is also a feature in the prescribing information. I don't know the mechanism of that, but it seems to be consistent, but it's seen a small fraction of patients.
Treatment-emergent AEs led to treatment discontinuation [of sacituzumab govitecan] in only 6%, [which is] impressive. Dose delay is more common [with this therapy, as seen in 66% of patients]. Approximately one-third of patients needed a dose reduction. I also find that I use growth factor quite a bit with this agent. I usually give pegfilgrastim [Neulasta] after day 8 and if someone is neutropenic from a prior cycle, or had a delay from a prior cycle, that usually takes care of it. I've seen fatigue and [used] dose modification for that, [as well].
References:
1. Rugo HS, Bardia A, Marmé F, et al. Sacituzumab govitecan in hormone receptor–positive/human epidermal growth factor receptor 2–negative metastatic breast cancer. J Clin Oncol. 2022;40(29):3365-3376. doi:10.1200/JCO.22.01002
2. Tolaney SM, Bardia A, Marmé F, et al. Final overall survival (OS) analysis from the phase 3 TROPiCS-02 study of sacituzumab govitecan (SG) in patients (pts) with hormone receptor–positive/HER2-negative (HR+/HER2–) metastatic breast cancer (mBC). J Clin Oncol. 2023;41(suppl 16):1003. doi:10.1200/JCO.2023.41.16_suppl.1003
How BCMA CAR T-Cell Therapy Provides Later-Line Options in R/R Multiple Myeloma
May 10th 2024During a Case-Based Roundtable® event, Abdullah Khan, MBBS, discussed the different outcomes with idecabtagene vicleucel in patients with relapsed/refractory multiple myeloma in both the clinic and real-world settings in the second article of a 2-part series.
Read More
Leslie Reviews Relevant Data for Treatment of Relapsed/Refractory CLL
May 8th 2024During a Case-Based Roundtable® event, Lori A. Leslie, MD, discussed Bruton tyrosine kinase inhibition options for a patient with relapsed/refractory chronic lymphocytic leukemia in the first article of a 2-part series.
Read More
Breast Cancer Leans into the Decade of Antibody-Drug Conjugates, Experts Discuss
September 25th 2020In season 1, episode 3 of Targeted Talks, the importance of precision medicine in breast cancer, and how that vitally differs in community oncology compared with academic settings, is the topic of discussion.
Listen
Key Takeaways From QOL and Use of Steroids With IO-Based RCC Regimens
May 6th 2024During a Case-Based Roundtable® event, Ulka Vaishampayan, MBBS, discussed the safety and quality-of-life data for ipilimumab plus nivolumab in patients with advanced renal cell carcinoma in the second article of a 2-part series.
Read More